Search for content, post, videos

AstraZeneca’s Lynparza approved in the EU in ovarian cancer

David Fredrickson
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. The approval by the European Commission was based on a bio
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.